Intercept EASL data continue to fuel investor concerns

Additional data presented Thursday at EASL for Intercept's Ocaliva obeticholic acid (OCA) to treat NASH address some lingering efficacy questions from physicians, but safety signals and Intercept’s latest analysis methods continue to spook investors as the company's shares fell $15.93 (13%) to $104.75.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported in February that Ocaliva met one of two primary endpoints vs. placebo in the Phase III REGENERATE trial for non-alcoholic steatohepatitis, showing a significant improvement in fibrosis without worsening of NASH, but missing the primary endpoint of NASH resolution with no worsening of liver fibrosis...